Southern Cross Acquisition II
SCATR · NASDAQ
SCATR key statistics
- Market cap
- —
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 93.86K
- Volume
- 38.40K
- Open price
- $0.1202
- High today
- $0.1284
- Low today
- $0.1202
- 52 Week high
- $0.15
- 52 Week low
- $0.115
Southern Cross Acquisition II (SCATR) at a glance
Southern Cross Acquisition II (SCATR) last traded at $0.1213, with a price-to-earnings ratio of 0.00.
Today the stock has traded between $0.1202 and $0.1284. The current price is 0.9% above the day's low and 5.5% below its high.
Volume so far is 38.40K shares, below the average of 93.86K shares a day.
Over the past year Southern Cross Acquisition II has ranged from $0.115 to $0.15, and now sits 18% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- RDARRaadr$0.0002−16.67%
- AXGSolowin Holdings$0.04−25.65%
- AEFIAmerican EcoFuels$0.0009+12.50%
- SHFSSHF Holdings$0.1158+23.19%
- DVLTDatavault AI$0.067−49.55%
- MASNMaison Luxe$0.0002+0.00%
- XXII22nd Century Group$0.1048+18.55%
- NBNDNetBrands$0.0007+0.00%
- NEXRNexera Technologies$0.5454+21.77%
- TIPSTianrong Internet Products & Services$0.0011+57.14%
- AITXArtificial Intelligence Technology Solutions$0.0008−20.00%
Newly listed
Companies that went public in the past six weeks
- LYCALycia Therapeutics$26.11−9.50%
- DAVIDAVION HEALTHCARE$3.00−26.29%
- TCXBTCGX Acquisition Corp. II$10.28+0.10%
- CTYCITY THERAPEUTICS$20.86+0.34%
- IAMIambic Therapeutics$14.00−2.85%
- AMROAmaero$6.04+12.48%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.23−0.49%
- TRXBTRex Bio$13.79−0.58%
- RTSNRetension Pharmaceuticals$13.52−5.06%
- PAXGUPine Tree Acquisition$10.00−0.20%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.20+1.36%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.